Skip to main content
Clinical Trials/NCT04423198
NCT04423198
Unknown
Not Applicable

HEAD Injury Serum Markers and Multi-modalities for Assessing Response to Trauma II

BRAINBox Solutions Inc11 sites in 1 country2,000 target enrollmentDecember 31, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Mild Traumatic Brain Injury
Sponsor
BRAINBox Solutions Inc
Enrollment
2000
Locations
11
Primary Endpoint
Correlation of mild traumatic brain injury diagnosis using the BRAINBox TBI Test compared to the Expert Clinical Diagnosis
Last Updated
4 years ago

Overview

Brief Summary

The goal of HeadSMART II (HEAD injury Serum markers and Multi-modalities for Assessing Response to Trauma II) is to develop an In-Vitro Diagnostic, the BRAINBox TBI test, to aid in the diagnosis and prognosis of patients with mild traumatic brain injury, by incorporating blood biomarkers, clinical assessments, and tools to measure associated neurocognitive impairments.

Detailed Description

This study proposes to collect data using a multi-modality approach including blood biomarkers, clinical assessments, neurocognitive performance, and neuropsychological characteristics, to identify subjects with a mild Traumatic Brain Injury (TBI) and their likelihood of chronic symptoms. This is an observational study with an expectation of enrolling up to 2000 subjects. These subjects will include the intended use population, subjects presenting to the Emergency Department or Urgent Care with a blunt head trauma. Data will be collected across four time points, T=0, 14 days, 30 days and 90 days, to allow for building and validating the algorithms for both diagnosis and prognosis claims. Control populations, healthy and trauma only (no head trauma) will be included for assay development. Data will be collected for these groups at T=0 and 14 days (trauma control only).

Registry
clinicaltrials.gov
Start Date
December 31, 2020
End Date
December 2021
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age \>=18 years
  • Ability to provide a blood sample; within 96 hours of injury
  • Ability to provide informed consent. Consent may be obtained with assistance of a legally authorized representative (LAR)
  • Must present to the Emergency Department (ED) or Urgent Care (UC) with a blunt head trauma

Exclusion Criteria

  • Glasgow Coma Scale (GCS) score \< 13, as presented in ED at time of screening
  • Need for general anesthesia at the time of presentation in the ED
  • Diagnosed dementia requiring assistance for daily living
  • Any head trauma requiring medical attention from a physician within the last 6 months
  • Received chemotherapy or radiation within the last year
  • History of stroke with disabling outcomes, brain tumor, epilepsy or intracranial surgery/hemorrhage
  • Psychiatric hospitalization in the last 90 days
  • Blood transfusion within the prior 4 weeks
  • Non-working telephone number
  • Current participant in an interventional clinical trial

Outcomes

Primary Outcomes

Correlation of mild traumatic brain injury diagnosis using the BRAINBox TBI Test compared to the Expert Clinical Diagnosis

Time Frame: 30 days

Sensitivity and specificity of the diagnosis as compared to a clinical diagnosis by an expert committee

Determine the risk stratification of having symptoms at 14, 30 and 90 days, for subjects with mild traumatic brain injury using the BRAINBox TBI Test results.

Time Frame: up to 90 days

Sensitivity and specificity of the risk for chronic symptoms as compared to the post-concussion symptoms at predefined time points

Study Sites (11)

Loading locations...

Similar Trials